Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: tanezumab, fulranumab, fasinumab +2 | 0.81 |
| trials ClinicalTrials.gov | 47 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 331 Parkinson's papers of 18,701 | 0.24 |
| pathways Reactome | 19 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 5388
Sealed predictions
- NGF in dopamine neurons, braak-0.16 (p 0.680) → -0.22 (p 0.569)receipt 5396
Swarm cases
receipt 5396: NGF in dopamine neurons, braak
- power
- full sample -0.06 (p 0.807, n 18), 95% CI -0.51 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.11 (p 0.671, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.02 (p 0.942, n 18). could be the mix.
- skeptic
- leave-one-out range -0.19 to +0.04, sign flips 4; without severely affected donors -0.06 (p 0.807, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NGF in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts